Research programme: ion channel therapeutics - Abilita Bio

Drug Profile

Research programme: ion channel therapeutics - Abilita Bio

Alternative Names: Ion channel therapeutics - Ab7; Ion channel therapeutics - Ab8

Latest Information Update: 27 Sep 2016

Price : $50

At a glance

  • Originator Abilita Bio
  • Class Antibodies
  • Mechanism of Action Ion channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Unspecified

Highest Development Phases

  • Research Unspecified

Most Recent Events

  • 22 Sep 2016 Research programme: ion channel therapeutics - Abilita Bio is available for licensing as of 22 Sep 2016. http://www.abilitabio.com/
  • 20 Sep 2016 Early research in Undefined indication (unspecified route)
  • 20 Sep 2016 Abilita Bio enters into a multi-target proof of concept agreement with an undisclosed global pharmaceutical company
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top